Stockwatch: Can bankers break biotech?
This article was originally published in Scrip
The recent outpouring of soul searching, introspection and discussion prompted by the parting editorial from Greg Smith, a now ex-Goldman Sachs investment banker, has had little linkage to the biotechnology sector. [Smith proposed in his resignation letter that career progression at Goldman Sachs is now contingent not on making money for its investor clients but on making money for Goldman Sachs.]
You may also be interested in...
Johnson & Johnson’s divisional recoveries were in contrast to the declines of Biogen’s franchises but both companies had a competitive pressure and a drug pricing issue.
With the latest Delta variant wave in the rear-view mirror, vaccine and antiviral sales, and their impact on full-year guidance, are likely to remain the big swing factors in third-quarter earnings season.
Patient selection is held out as the Achilles heel of clinical trial success. But a surprise and fortunate finding in Pfizer’s gene therapy trial has already resulted in tightened recruitment criteria, thanks to genetic analysis.